Home ACELYRIN

ACELYRIN

In operation
IPO
Antibody Drug Developer
Basic
Enterprise Profile

Basic Information

ACELYRIN is a biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of promising drug candidates, leveraging its expertise to rapidly bring these drugs to patients and provide them with life-changing new therapeutic options. The company’s product, Izokibep, is a unique antibody mimetic interleukin-17A (IL-17A) inhibitor designed to overcome the limitations of monoclonal antibodies.
ACELYRIN, INC.
LosAngeles,California,United States of America
15~50 people
January 01, 2020
info@acelyrin.com

Enterprise Profile

Industrial Sector
New Drug Development Biological Drug Production
Technology
Biotechnology
Concept
Therapeutic Products Department of Pharmacy
Application Scenarios
Innovative Drugs Monoclonal Antibody